NICE says Bayer's CDF liver cancer drug is not cost-effective

19 August 2016

The National Institute for Health and Care Excellence (NICE) has said in draft guidance published today that German pharma major Bayer’s (BAYN: DE) liver cancer drug Nexavar (sorafenib) – which is currently available on the Cancer Drugs Fund (CDF) – is not value for money.

NICE, the cost-effectiveness watchdog for England and Wales, originally published guidance in 2010 which said that sorafenib was not cost effective. It was then made available through the CDF. NICE is reconsidering sorafenib as part of its program to appraise drugs that are currently available on the CDF. As part of the reappraisal, Bayer presented further evidence which was not included in their original submission. The price of sorafenib is also lower than at the time of the original appraisal.

The committee reviewed the resubmission for sorafenib and concluded that there was still considerable uncertainty about the overall survival benefit and it was unclear how long patients would take the medicine.Sorafenib was not considered cost-effective as these uncertainties were not compensated by the new price.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK